Revision History

Update: added October 2026 drug development partnerships (Generate, Divergence, BigHat, Enveda, The Column Group, BMS), the Mithril Medicine acquisition, and researcher programs, with technical reports cited

Improve internal links (2026-10-13)

Correction: Xaira, Edison and Manifold Bio were quoted, not described as early participants; beta, not public beta

Correction: no proposal form on the post; the reverse transcriptase itself was already known; TNW author added (verifier V1)

Correction: Opus 5.5 was deployed with safeguards 'similar to' (not 'the same as') Fable 5.1's and the 'impeded' wording was unsupported; Benchling press release was Oct 20, 2025 (not the Coefficient Bio deal day); wet-lab quote now verbatim from Reuters; Proteinbase quotes now match '$1 million+'. Update: Sep 2026 research group and lab (BSL-1/2, human-run), ART reverse-transcriptase discovery, call for proposals, competition tracks, Reuters robotics reporting, Novo Nordisk collaboration.

Link [Twist Bioscience] to the new twist_bioscience article

Verification fixes: Protocol QA methodology attribution; unsourced first-vertical and reception claims removed; schedule citation; non-cash prizes; LSVP wording; duplicate MCP link

Correction: all nine implementation partners were named at launch, not added later; adds the 2026 protein design campaigns, the Adaptyv Bio competition, the Life Sciences Verification Program and Anthropic's wet lab

Added 6 contextual internal links

Auto-saved before update

No summary provided